Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

 
• By Joseph Haas

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.

Business teamwork puzzle pieces.
Endo will acquire its long-time partner BioSpecifics in a $658m tender

More from Deals

More from Business